| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EURURO.2007.08.039 |
| P698 | PubMed publication ID | 17804150 |
| P50 | author | Xavier Gamé | Q60660727 |
| P2093 | author name string | Pascal Rischmann | |
| Bernard Malavaud | |||
| Evelyne Castel-Lacanal | |||
| Philippe Marque | |||
| Xavier De Boissezon | |||
| Isabelle Thiry-Escudié | |||
| Youssef Bentaleb | |||
| P433 | issue | 3 | |
| P921 | main subject | urinary tract infection | Q221668 |
| P304 | page(s) | 613-618 | |
| P577 | publication date | 2007-08-28 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections | |
| P478 | volume | 53 |
| Q38181065 | Advances in the management of neurogenic detrusor overactivity in multiple sclerosis |
| Q37248174 | Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity |
| Q37496473 | Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis |
| Q38222194 | Botulinum toxin for symptomatic therapy in multiple sclerosis |
| Q37581341 | Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity |
| Q48500221 | Catheter-associated urinary tract infections in persons with neurogenic bladders |
| Q36395728 | Clinical uses of botulinum neurotoxins: current indications, limitations and future developments |
| Q38564108 | Current and potential urological applications of botulinum toxin A. |
| Q85985772 | Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury |
| Q92461109 | Early urinary tract infection after spinal cord injury: a retrospective inpatient cohort study |
| Q60923860 | Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis |
| Q38115204 | Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review |
| Q38184544 | Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice |
| Q37812561 | Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity |
| Q26765052 | How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? |
| Q36855832 | Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment |
| Q41412205 | Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury. |
| Q48089934 | Macroplastique and Botox are superior to Macroplastique alone in the management of neurogenic vesicoureteric reflux in spinal cord injury population with presumed healthy bladders. |
| Q38794193 | Management of neurogenic bladder in patients with multiple sclerosis |
| Q40111907 | Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions |
| Q38233836 | OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury |
| Q26826756 | OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review |
| Q41477135 | Prevention of recurrent autonomic dysreflexia: a survey of current practice |
| Q27009094 | Prevention of urinary tract infections in patients with spinal cord injury |
| Q40259694 | Risk factors for symptomatic urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction |
| Q55314643 | Systematic review and practice policy statements on urinary tract infection prevention in adults with spina bifida. |
| Q38239522 | The evaluation and management of refractory neurogenic overactive bladder |
| Q37720749 | Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines |
| Q49073287 | Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. |
| Q38238993 | UTIs in patients with neurogenic bladder |
| Q39439599 | Understanding the Economic Impact of Neurogenic Lower Urinary Tract Dysfunction |
| Q26767308 | Urinary tract infection in the neurogenic bladder |
| Q49050573 | Urinary tract infections in patients with spinal cord injuries |
| Q90534364 | Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-Analysis |
| Q26851170 | Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review |
Search more.